Colorectal Cancer Clinical Trials

• Histologically confirmed rectal adenocarcinoma

• cT3, cT4, threatened CRM / MRF, EMVI (+), ≥N1

• Multidisciplinary tumor board decision for neoadjuvant treatment

• Tumor distance from the anal verge \<15 cm based on endoscopy or magnetic resonance imaging

• Patient 18 to 80 years old

• General health condition status WHO 0-1

• Absence of co-morbidities that may affect treatment

• Neutrophils \>1,500 / mm3, platelets \>100,000 / mm3, hemoglobin\> 10 g / dL, normal creatinine, and creatinine clearance\> 50 mL / min

• Signed informed consent of the patient